Four-Drug attack on deadly pancreatic cancer enters major trial
NCT ID NCT06361888
Summary
This study is testing whether adding two newer drugs (surufatinib and camrelizumab) to standard chemotherapy works better for people with metastatic pancreatic cancer. It will compare the new four-drug combination against the current two-drug standard. The main goal is to see if the new combination helps patients live longer. The trial is for adults newly diagnosed with advanced pancreatic cancer that has spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
Contact
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
Conditions
Explore the condition pages connected to this study.